Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H38N2O4.ClH |
| Molecular Weight | 479.052 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCCN(CCCCN1C(=O)CC2(CCCC2)CC1=O)[C@@H]3COC4=CC=CC(OC)=C4C3
InChI
InChIKey=QYFHCFNBYQZGKW-BDQAORGHSA-N
InChI=1S/C26H38N2O4.ClH/c1-3-13-27(20-16-21-22(31-2)9-8-10-23(21)32-19-20)14-6-7-15-28-24(29)17-26(18-25(28)30)11-4-5-12-26;/h8-10,20H,3-7,11-19H2,1-2H3;1H/t20-;/m0./s1
| Molecular Formula | C26H38N2O4 |
| Molecular Weight | 442.5909 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + ) |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Alnespirone [S 20499] is a potent and full agonist at pre- and postsynaptic serotonin 1A receptors. Alnespirone is the (+)-enantiomer, S 20244 is the racemate. In animal models, alnespirone demonstrated both anxiolytic and antidepressant activity and was undergoing phase II trials in these indications with Servier in France. However, development of Alnespirone was discontinued for anxiety disorders and major depressive disorder.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| In vivo comparison of two 5-HT1A receptors agonists alnespirone (S-20499) and buspirone on locus coeruleus neuronal activity. | 2003 Jan 10 |
|
| 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis. | 2005 Dec 5 |
Patents
Sample Use Guides
Rat model of depression: Alnespirone was administered twice daily via the oral route (2.5, 5, 10, 20 mg kg(-1) day(-1)). It was shown to protect against the elevation in escape failures caused by exposure to the uncontrollable aversive situation at 5 and 10 mg kg(-1) day(-1) p.o. (13+/-2 and 10+/-3 escape failures, respectively, vs. 9+/-2 escape failures in control rats).
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:39:23 GMT 2023
by
admin
on
Fri Dec 15 19:39:23 GMT 2023
|
| Record UNII |
5CPK6K625T
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9826391
Created by
admin on Fri Dec 15 19:39:23 GMT 2023 , Edited by admin on Fri Dec 15 19:39:23 GMT 2023
|
PRIMARY | |||
|
DTXSID90931874
Created by
admin on Fri Dec 15 19:39:23 GMT 2023 , Edited by admin on Fri Dec 15 19:39:23 GMT 2023
|
PRIMARY | |||
|
143413-69-8
Created by
admin on Fri Dec 15 19:39:23 GMT 2023 , Edited by admin on Fri Dec 15 19:39:23 GMT 2023
|
PRIMARY | |||
|
5CPK6K625T
Created by
admin on Fri Dec 15 19:39:23 GMT 2023 , Edited by admin on Fri Dec 15 19:39:23 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|